Bill
HB 4984
The bill promotes the use of generic antipsychotics in West Virginia Medicaid to reduce costs while safeguarding patient safety and treatment effectiveness.
HB 4984 (West Virginia, 2026)
Genric use of antipsychotics in Medicaid
Overview
- Purpose: The bill addresses the use of generic antipsychotic medications within the West Virginia Medicaid program. It aims to regulate or standardize when and how generic antipsychotics are prescribed, dispensed, or preferred within Medicaid, with an emphasis on cost, access, and clinical appropriateness.
- Session and jurisdiction: 2026 session; West Virginia.
Key Provisions (substantive content)
- Generic preference or utilization: The bill likely establishes a framework to encourage or require the use of generic antipsychotics when medically appropriate, with the goal of reducing costs for Medicaid while maintaining patient safety and treatment effectiveness.
- Prescribing and dispensing rules: It may set criteria for when pharmacists and prescribers should favor a generic antipsychotic over brand-name products, including steps to ensure therapeutic equivalence and clinically appropriate substitution.
- Clinical and safety considerations: Provisions might include safeguards to prevent unintended interruptions in treatment, require communication with patients and providers about substitution, and allow exceptions for specific clinical indications or patient histories.
- Cost containment: The bill likely ties into Medicaid’s budget by promoting lower-cost generic options and enabling managed care or waiver programs to implement preferred drug lists or formulary decisions related to antipsychotics.
- Oversight and enforcement: Provisions could establish reporting, oversight mechanisms, and penalties or corrective actions for noncompliance by providers, pharmacies, or managed care organizations administering Medicaid.
- Effective date and transition: The bill would specify an effective date and any transition period for implementing generic-use provisions, including deadlines for state agencies, Medicaid managed care entities, and providers.
Who is affected
- Medicaid enrollees receiving antipsychotic medications, including patients in managed care or fee-for-service programs.
- Prescribers (physicians, psychiatrists, nurse practitioners) and other clinicians who write prescriptions for antipsychotics within Medicaid.
- Pharmacists and pharmacies participating in Medicaid, who would implement substitution and formulary rules.
- Medicaid program administrators, managed care organizations, and the Department of Health and Human Resources (or its Medicaid office) responsible for implementing drug utilization policies.
Procedural and timeline aspects
- Introduction and committee path: Introduced January 30, 2026; referred to the House Health and Human Resources committee.
- Legislative actions: Markup discussions noted on February 18, 2026, indicating committee consideration and potential amendments.
- Sponsors: Primary sponsor not listed; co-sponsor noted as Evan Worrell.
- Implementation timeline: The bill would specify an effective date after passage and potential phased implementation for formulary changes and substitution rules.
Notes and considerations
- The provided text includes non-text encoding content that obscures some specifics. The summary above reflects typical elements of a bill focused on generic antipsychotic use within Medicaid, including cost containment, substitution standards, and patient safety safeguards.
- For a precise, clause-by-clause understanding, the official bill text, fiscal notes, and committee amendments should be reviewed once available.
If you’d like, I can adapt this into a brief one-page summary for distribution or expand any section with hypothetical examples (e.g., a scenario of generic substitution in a Medicaid pharmacy benefit).
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
